Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding trial
Phase of Trial: Phase I/II
Latest Information Update: 18 Jan 2018
At a glance
- Drugs Ponatinib (Primary) ; Antineoplastics
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- Acronyms MATCHPOINT
- 16 Sep 2017 Status changed from active, no longer recruiting to completed.
- 03 Jun 2017 Status changed from recruiting to active, no longer recruiting.
- 10 Dec 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network record.